Oragenics (OGEN) 10-Q13 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - $ / shares	9 Months Ended
Cover - $ / shares	Sep. 30, 2024	Nov. 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-32188
Entity Registrant Name	ORAGENICS, INC.
Entity Central Index Key	0001174940
Entity Tax Identification Number	59-3410522
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	1990 Main Street
Entity Address, Address Line Two	Suite 750
Entity Address, City or Town	Sarasota
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34236
City Area Code	813
Local Phone Number	286-7900
Title of 12(b) Security	Common Stock
Trading Symbol	OGEN
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,212,680
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,144,049	$ 3,483,501
Prepaid expenses and other current assets	969,294	382,273
Total current assets	4,113,343	3,865,774
Prepaid research and development expense	1,090,750	1,090,750
Operating lease right-of-use assets		9,811
Total assets	5,204,093	4,966,335
Current liabilities:
Accounts payable and accrued expenses	1,607,114	1,475,667
Short-term notes payable	519,392	312,703
Operating lease liabilities - Current		9,811
Total liabilities	2,126,506	1,798,181
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, -0- and -0- Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at September 30, 2024 and December 31, 2023, respectively	1,592,723	1,592,723
Common stock, $0.001 par value; 350,000,000 shares authorized and 9,387,547 and 3,080,693 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	9,388	3,081
Additional paid-in capital	214,912,523	207,790,604
Accumulated Deficit	(213,437,047)	(206,218,254)
Total shareholders’ equity	3,077,587	3,168,154
Total liabilities and shareholders’ equity	$ 5,204,093	$ 4,966,335

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	9,387,547	3,080,693
Common stock, shares outstanding	9,387,547	3,080,693
Series A Preferred Stock [Member]
Preferred stock, shares outstanding	5,417,000	5,417,000
Series B Preferred Stock [Member]
Preferred stock, shares outstanding	4,050,000	4,050,000
Series C Preferred Stock [Member]
Preferred stock, shares outstanding	0	0
Series F Preferred Stock [Member]
Preferred stock, shares outstanding	7,488,692	7,488,692

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Grant revenue		$ 7,466		$ 37,653
Operating expenses:
Research and development	879,041	769,350	2,449,234	4,448,623
General and administrative	1,558,239	1,332,562	4,754,149	3,697,609
Total operating expenses	2,437,280	2,101,912	7,203,383	8,146,232
Loss from operations	(2,437,280)	(2,094,446)	(7,203,383)	(8,108,579)
Other income (expense):
Interest income	9,466	50,613	35,106	171,768
Interest expense	(9,971)	(14,170)	(18,859)	(18,360)
Other income		45,118		46,863
Foreign currency exchange net	(25,085)		(31,659)
Total other income (expense), net	(25,590)	81,561	(15,412)	200,271
Loss before income taxes	(2,462,870)	(2,012,885)	(7,218,795)	(7,908,308)
Income tax benefit
Net loss	$ (2,462,870)	$ (2,012,885)	$ (7,218,795)	$ (7,908,308)
Basic net loss per share	$ (0.38)	$ (0.85)	$ (1.49)	$ (3.70)
Diluted net loss per share	$ (0.38)	$ (0.85)	$ (1.49)	$ (3.70)
Shares used to compute basic net loss per share	6,528,064	2,356,065	4,857,182	2,136,340
Shares used to compute diluted net loss per share	6,528,064	2,356,065	4,857,182	2,136,340

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances at Dec. 31, 2022	$ 2,025	$ 1,592,723	$ 196,977,071	$ (185,562,517)	$ 13,009,302
Balance, shares at Dec. 31, 2022	2,024,657	9,467,000
Compensation expense relating to option issuances			79,966		79,966
Net loss				(2,844,837)	(2,844,837)
Balances at Mar. 31, 2023	$ 2,025	$ 1,592,723	197,057,037	(188,407,354)	10,244,431
Balance, shares at Mar. 31, 2023	2,024,657	9,467,000
Balances at Dec. 31, 2022	$ 2,025	$ 1,592,723	196,977,071	(185,562,517)	13,009,302
Balance, shares at Dec. 31, 2022	2,024,657	9,467,000
Net loss					(7,908,308)
Balances at Sep. 30, 2023	$ 2,549	$ 1,592,723	198,372,874	(193,470,825)	6,497,321
Balance, shares at Sep. 30, 2023	2,569,385	9,467,000
Balances at Mar. 31, 2023	$ 2,025	$ 1,592,723	197,057,037	(188,407,354)	10,244,431
Balance, shares at Mar. 31, 2023	2,024,657	9,467,000
Compensation expense relating to option issuances			63,628		63,628
Net loss				(3,050,586)	(3,050,586)
Balances at Jun. 30, 2023	$ 2,025	$ 1,592,723	197,120,665	(191,457,940)	7,257,473
Balance, shares at Jun. 30, 2023	2,024,657	9,467,000
Compensation expense relating to option issuances			(1,591)		(1,591)
Net loss				(2,012,885)	(2,012,885)
Compensation expense relating to restricted stock issuances	$ 120		404,396		404,516
Compensation expense relating to restricted stock issuances, shares	140,000
Common stock issued in private placement	$ 404		849,404		849,808
Common stock issued in private placement, shares	404,728
Balances at Sep. 30, 2023	$ 2,549	$ 1,592,723	198,372,874	(193,470,825)	6,497,321
Balance, shares at Sep. 30, 2023	2,569,385	9,467,000
Balances at Dec. 31, 2023	$ 3,081	$ 1,592,723	207,790,604	(206,218,254)	3,168,154
Balance, shares at Dec. 31, 2023	3,080,693	16,955,197
Compensation expense relating to option issuances			69,344		69,344
Sale of Common Stock	$ 1,400		1,837,201		1,838,601
Sale of Common Stock, shares	1,400,000
Net loss				(2,450,833)	(2,450,833)
Balances at Mar. 31, 2024	$ 4,481	$ 1,592,723	209,697,149	(208,669,087)	2,625,266
Balance, shares at Mar. 31, 2024	4,480,693	16,955,197
Balances at Dec. 31, 2023	$ 3,081	$ 1,592,723	207,790,604	(206,218,254)	3,168,154
Balance, shares at Dec. 31, 2023	3,080,693	16,955,197
Net loss					(7,218,795)
Balances at Sep. 30, 2024	$ 9,388	$ 1,592,723	214,912,523	(213,437,047)	3,077,587
Balance, shares at Sep. 30, 2024	9,387,547	16,955,197
Balances at Mar. 31, 2024	$ 4,481	$ 1,592,723	209,697,149	(208,669,087)	2,625,266
Balance, shares at Mar. 31, 2024	4,480,693	16,955,197
Compensation expense relating to option issuances			58,220		58,220
Sale of Common Stock	$ 1,100		946,900		948,000
Sale of Common Stock, shares	1,100,000
Net loss				(2,305,090)	(2,305,090)
Balances at Jun. 30, 2024	$ 5,581	$ 1,592,723	210,702,269	(210,974,177)	1,326,396
Balance, shares at Jun. 30, 2024	5,580,693	16,955,197
Compensation expense relating to option issuances			330,802		330,802
Sale of Common Stock	$ 3,807		3,879,452		3,883,259
Sale of Common Stock, shares	3,806,854
Net loss				(2,462,870)	(2,462,870)
Balances at Sep. 30, 2024	$ 9,388	$ 1,592,723	$ 214,912,523	$ (213,437,047)	$ 3,077,587
Balance, shares at Sep. 30, 2024	9,387,547	16,955,197

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (7,218,795)	$ (7,908,308)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		27,391
Gain on sale of property and equipment		(22,443)
Stock-based compensation expense	458,366	546,519
Changes in operating assets and liabilities:
Other receivables		(35,104)
Prepaid expenses and other current assets	49,951	1,443,563
Operating lease right of use assets	9,811	323,103
Deposits		9,340
Accounts payable and accrued expenses	131,449	(572,396)
Change in operating lease liabilities	(9,811)
Net cash used in operating activities	(6,579,029)	(6,188,335)
Cash flows from investing activities:
Proceeds from sale of property and equipment		63,715
Net cash provided by (used in) investing activities		63,715
Cash flows from financing activities:
Payments on short-term notes payable	(430,283)	(385,329)
Net proceeds from issuance of common stock	6,669,860	849,808
Net cash provided by (used in) financing activities	6,239,577	464,479
Net decrease in cash and cash equivalents	(339,452)	(5,660,141)
Cash and cash equivalents at beginning of period	3,483,501	11,426,785
Cash and cash equivalents at end of period	3,144,049	5,766,644
Supplemental disclosure of cash flow information:
Interest paid	18,859	3,347
Non-cash investing and financing activities:
Borrowings under short term notes payable for prepaid expense	$ 636,972	$ 611,109

Organization

Organization	9 Months Ended
Organization	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Oragenics, Inc. (the “Company” or “we”, or “our”) was incorporated in November 1996. We are a development-stage company dedicated to the research and development of nasal delivery pharmaceutical medications and therapies. Commencing in December of 2023, we are focused on the development of medical products that treat brain related illnesses and diseases and our lead product candidate and focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (“mTBI” or “Concussion”). Prior to the purchase of our lead asset ONP-002, starting in May 2020 and through December 31, 2023 our lead asset was a nasal delivery vaccine candidate to provide long-lasting immunity from SARS-CoV-2, which causes COVID-19. Currently research and development activities related to the nasal vaccine platform and our lantibiotic program are inactive, we will evaluate alternative opportunities for these programs moving forward as we continue to strengthen our focus and expertise on our intranasal drug delivery platform and drug candidates.

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements as of September 30, 2024 and December 31, 2023 and for the three and nine months ended September 30, 2024 and 2023, have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim condensed consolidated financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete condensed consolidated financial statements. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ended December 31, 2024, or any future period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2024. Going Concern Consideration The Company has incurred recurring losses and negative cash flows from operations since inception. To date, the Company has not generated significant revenues from operations. The Company incurred a net loss of $ 7,218,795 6,579,029 213,437,047 The Company expects to incur substantial expenditures to further develop its technologies. The Company believes its working capital at September 30, 2024 will be sufficient to meet the business objectives as presently structured only through the fourth quarter of 2024. As such, there is substantial doubt that we can continue as a going concern beyond that date. As a result, the Company has implemented certain cost-saving initiatives, including the termination of its lease of the corporate office located in Tampa, Florida. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. In the nine-month period ended September 30, 2024 the Company secured funding through the sale of approximately 5.6 5 7.7

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Consolidation The condensed consolidated financial statements include the accounts of Oragenics, Inc. and our wholly owned subsidiaries Noachis Terra, Inc. (“NTI”) and Oragenics Australia Pty Ltd. All intercompany balances and transactions have been eliminated. New Accounting Standards There are no additional accounting pronouncements issued or effective during the nine months ended September 30, 2024, that have had, or are expected to have, a material impact on our condensed consolidated financial statements. Use of Estimates The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the condensed consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations. Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.

Prepaid Expense, Deposits, and

Prepaid Expense, Deposits, and Other Current Assets	9 Months Ended
Prepaid Expense, Deposits, and Other Current Assets	Sep. 30, 2024
Prepaid Expense Deposits And Other Current Assets
Prepaid Expense, Deposits, and Other Current Assets	4. Prepaid Expense, Deposits, and Other Current Assets Prepaid expenses, deposits, and other current assets consist of the following at September 30, 2024 and December 31, 2023: Schedule of Prepaid Expense and Other Current Assets September 30, 2024 December 31, 2023 Prepaid research and development expense, current $ 386,035 $ — Prepaid insurance 531,701 334,940 Other prepaid expense, current 51,558 47,333 Prepaid research and development expense, long-term 1,090,750 1,090,750 Total prepaid expense, deposits, and other current assets $ 2,060,044 $ 1,473,023

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
Accounts Payable and Accrued Expenses	Sep. 30, 2024
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	5. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following as of September 30, 2024, and December 31, 2023: Schedule of Accounts Payable and Accrued Expenses September 30, 2024 December 31, 2023 Accounts payable trade $ 1,513,287 $ 1,244,947 Accrued expenses 65,657 222,739 Accrued Vacation 28,170 7,981 Total accounts payable and accrued expenses $ 1,607,114 $ 1,475,667

Short-Term Notes Payable

Short-Term Notes Payable	9 Months Ended
Short-Term Notes Payable	Sep. 30, 2024
Debt Disclosure [Abstract]
Short-Term Notes Payable	6. Short-Term Notes Payable The Company had the following short-term notes payable as of September 30, 2024 and December 31, 2023: Summary of Short-Term Notes Payable September 30, 2024 December 31, 2023 Insurance premium financing of $ 636,972 611,109 67,277 54,366 9.55 $ 519,392 $ 312,703 Short-term notes payable $ 519,392 $ 312,703 The Company’s policy renewals were completed in July of 2024.

Shareholders_ Equity

Shareholders’ Equity	9 Months Ended
Shareholders’ Equity	Sep. 30, 2024
Equity [Abstract]
Shareholders’ Equity	7. Shareholders’ Equity Common Stock Other Share Issuances Pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-269225) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission; on March 1, 2024, through an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity, LLC as representative (the “Representative”) of the underwriters (collectively, the “Underwriters”), the Company sold 1,400,000 1.50 1.395 210,000 The Company also agreed to issue warrants to the designees of the Representative exercisable one hundred eighty (180) days after February 27, 2024 February 27, 2029 1.875 2.1 The Underwriting Agreement contains customary representations, warranties and agreements by the Company, conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. On June 25, 2024 the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Dawson James Securities Inc. (“Dawson James” or the “Placement Agent”) pursuant to which the Company engaged Dawson James as the placement agent for a registered public offering (the “Offering”) of an aggregate of 1,100,000 0.001 1.00 7.00 75,000 5 125 The Offering resulted in gross proceeds to the Company of $ 1.1 The Placement Agency Agreement contains customary representations, warranties and agreements, conditions to closing, indemnification obligations of the Company, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions. On September 4, 2024, the Company entered into a second placement agency agreement (the “ Second Placement Agency Agreement”) with Dawson James Securities Inc. (“Dawson James” or the “Placement Agent”) pursuant to which the Company engaged Dawson James as the placement agent for a registered public offering by the Company (the “Offering”) of an aggregate of (i) 8,106,584 0.001 The Offering Price was $ 0.55 0.549 0.001 The Offering closed on September 5, 2024. Upon the closing of the Offering, the Company issued and sold 3,078,378 5,028,206 Immediately after the Offering, the Company had 8,659,071 5,028,206 5,028,206 3,888,501 1,139,705 The Placement Agent agreed to use its reasonable best efforts to arrange for the sale of the Common Stock and Pre-Funded Warrants. The Company agreed to pay the Placement Agent a placement agent fee in cash equal to 7.00 125,000 5 125 The Offering resulted in gross proceeds to the Company of approximately $ 4.45 3.79 The Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions. The Offering was made pursuant to a registration statement on Form S-1 (File No. 333-281618), which was declared effective by the Securities and Exchange Commission on September 3, 2024. The Company also entered into a warrant agency agreement with its transfer agent, Continental Stock Transfer & Trust Company, who will act as warrant agent for the Company, setting forth the terms and conditions of the Pre-Funded Warrants sold in the Offering (the “Warrant Agency Agreement”).

At The Market

At The Market	9 Months Ended
At The Market	Sep. 30, 2024
At Market
At The Market	8. At The Market On October 11, 2024, the Company entered into an At-the-Market Sales Agreement (the “ATM Agreement”) with Dawson James Securities Inc. (“Dawson James” or the “Sales Agent”) pursuant to which the Company may issue and sell, from time to time, shares of its common stock (the “Shares”), depending on market demand, with the Sales Agent acting as the sales agent or principal (the “Offering”). Sales of the Shares may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the NYSE American. The Agent will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf, consistent with the Agent’s normal trading and sales practices, under the terms and subject to the conditions set forth in the ATM Agreement. The Company has no obligation to sell any of the Shares. The Company may instruct the Agent not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the ATM Agreement. The Company will pay the Agent a commission of up to 3.0 30,000 2,500 Any sales of Shares under the ATM Agreement will be made pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-269225), including the related prospectus, filed with the Securities and Exchange Commission (the “SEC”) on January 13, 2023, and declared effective on January 25, 2023, as supplemented by the prospectus supplement dated October 11, 2024, and any applicable additional prospectus supplements related to the Offering that form a part of the Registration Statement. The aggregate market value of Shares eligible for sale in the Offering and under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. The prospectus supplement filed with the SEC on October 11, 2024, is offering Shares having an aggregate offering price of $ 10,000,000 10,000,000 The Company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. The precise amount and timing of the application of these proceeds will depend upon a number of factors, such as the timing and progress of our research and development efforts, our funding requirements and the availability and costs of other funds. As of November 13, 2024 there have been no shares sold under the ATM Agreement. Previously, on August 8, 2024, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Ascendiant Capital Markets, LLC, as sales agent (the “Agent”), pursuant to which the Company may offer and sell through or to the Agent (the “ATM”) up to $ 10.0

Warrants

Warrants	9 Months Ended
Warrants	Sep. 30, 2024
Warrants
Warrants	9. Warrants The Company’s outstanding and exercisable warrants as of September 30, 2024 are presented below: Schedule of Warrants Outstanding and Exercisable Number of Warrants Weighted Average Exercise Price Warrants outstanding at December 31, 2023 260,995 $ 82.55 Issued 530,329 0.90 Expired (43,862 ) 89.60 Warrants outstanding at September 30, 2024 747,462 22.98 Warrants Exercise Price Expiration 10,888 $ 186.00 11/8/2024 153,334 $ 75.00 5/1/2025 52,911 $ 60.00 7/17/2025 70,000 $ 1.88 2/27/2029 55,000 (1) $ 1.25 6/29/2029 405,329 (2) $ 0.69 9/4/2029 1,139,705 (3) $ 0.001 1,887,167 All outstanding warrants are classified as equity on the Company’s Condensed Consolidated Balance Sheets. (1) – Dawson James Placement Agent warrants are not exercisable until December 23, 2024. (2) – Dawson James Placement Agent warrants are not exercisable until March 4, 2025. (3) – Pre-Funded Warrants from September 5, 2024 financing not yet converted as of November 13, 2024.

Stock Compensation Plan

Stock Compensation Plan	9 Months Ended
Stock Compensation Plan	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock Compensation Plan	10. Stock Compensation Plan On September 29, 2023, the Board of Directors approved an amendment to the 2021 Equity Incentive Plan (the “Incentive Plan”) to increase the authorized shares available under the Incentive Plan by 1,000,000 The Incentive Plan, as amended, provides aggregate number of shares of Common Stock that may be issued under the 2021 Plan will not exceed the sum of (i) 1,166,167 Options are granted at the fair market value of the Company’s stock on the date of the grant which determines the exercise price after the completion of the vesting period. Options can vest either immediately or over a period of up to three years from their respective grant dates and expire 10 years from the date of grant. A summary of stock option activity for the nine months ended September 30, 2024 is as follows: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2023 244,733 $ 20.17 8.73 $ 74,559 Granted 799,583 0.48 — $ — Expired (17,146 ) 28.44 — $ — Forfeited (4,667 ) 11.52 — $ — Outstanding at September 30, 2024 1,022,503 $ 4.67 9.06 $ — Exercisable at September 30, 2024 904,853 $ 5.03 8.97 $ — (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2023 and September 30, 2024; respectively. As of September 30, 2024, an aggregate of 1,022,503 3,664 Total compensation cost related to stock options was $ 330,802 402,805 458,365 546,399 195,296 one year

License and Royalty Agreements

License and Royalty Agreements	9 Months Ended
License and Royalty Agreements	Sep. 30, 2024
License And Royalty Agreements
License and Royalty Agreements	11. License and Royalty Agreements Inspirevax License On February 23, 2023, the Company entered into a Commercial License Agreement (the “Inspirevax License Agreement”) for its vaccine product candidate with Inspirevax Inc. (“Inspirevax”) pursuant to which Inspirevax granted the Company an exclusive worldwide license to use Inspirevax’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of Inspirevax (the “Inspirevax Technologies”) relating to its novel lipid-protein based intranasal adjuvants, to make, research, and develop an intra-nasal vaccine in combination with an antigen (“Combination Product”) to be used in an intranasal vaccine for use against diseases caused by coronaviruses and any genetic variants thereof to be sold by us. The Company agreed to pay in consideration for the Inspirevax License Agreement an upfront signing fee and to certain milestone payment obligations. As of September 30, 2024, none of the milestone payment obligations for the Inspirevax License Agreement have been met.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Three-Way Collaborative Agreement In May of 2023, the Company entered into a Collaborative Research Agreement (the “Collaboration”) with Inspirevax, and the National Research Council (the “Collaborators”) for research related to the Company’s vaccine product candidate. The Collaboration received non-dilutive funding from Consortium Québécois Sur La Découverte Du Médicament (the “CQDM”) a not-for-profit corporation governed by Canada created to promote, stimulate, and support drug research, development and discovery. The CQDM also provides funding for drug research and discovery projects. The project is budgeted to cost approximately $ 1.7 40 Ladenburg Thalmann Litigation On December 7, 2022, the Company entered into an investment banking engagement letter with Ladenburg Thalmann, (“Ladenburg”). The engagement letter was subsequently amended at various times (together with amendments to the “Engagement Letter”). The Company terminated the Engagement Letter as of August 15, 2023. Ladenburg sent the Company an invoice in the amount of $ 2,500,000

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The condensed consolidated financial statements include the accounts of Oragenics, Inc. and our wholly owned subsidiaries Noachis Terra, Inc. (“NTI”) and Oragenics Australia Pty Ltd. All intercompany balances and transactions have been eliminated.
New Accounting Standards	New Accounting Standards There are no additional accounting pronouncements issued or effective during the nine months ended September 30, 2024, that have had, or are expected to have, a material impact on our condensed consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the condensed consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations.
Net Loss Per Share	Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.

Prepaid Expense, Deposits, an_2

Prepaid Expense, Deposits, and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Prepaid Expense Deposits And Other Current Assets
Schedule of Prepaid Expense and Other Current Assets	Prepaid expenses, deposits, and other current assets consist of the following at September 30, 2024 and December 31, 2023: Schedule of Prepaid Expense and Other Current Assets September 30, 2024 December 31, 2023 Prepaid research and development expense, current $ 386,035 $ — Prepaid insurance 531,701 334,940 Other prepaid expense, current 51,558 47,333 Prepaid research and development expense, long-term 1,090,750 1,090,750 Total prepaid expense, deposits, and other current assets $ 2,060,044 $ 1,473,023

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following as of September 30, 2024, and December 31, 2023: Schedule of Accounts Payable and Accrued Expenses September 30, 2024 December 31, 2023 Accounts payable trade $ 1,513,287 $ 1,244,947 Accrued expenses 65,657 222,739 Accrued Vacation 28,170 7,981 Total accounts payable and accrued expenses $ 1,607,114 $ 1,475,667

Short-Term Notes Payable (Table

Short-Term Notes Payable (Tables)	9 Months Ended
Short-Term Notes Payable (Tables)	Sep. 30, 2024
Debt Disclosure [Abstract]
Summary of Short-Term Notes Payable	The Company had the following short-term notes payable as of September 30, 2024 and December 31, 2023: Summary of Short-Term Notes Payable September 30, 2024 December 31, 2023 Insurance premium financing of $ 636,972 611,109 67,277 54,366 9.55 $ 519,392 $ 312,703 Short-term notes payable $ 519,392 $ 312,703

Warrants (Tables)

Warrants (Tables)	9 Months Ended
Warrants (Tables)	Sep. 30, 2024
Warrants
Schedule of Warrants Outstanding and Exercisable	The Company’s outstanding and exercisable warrants as of September 30, 2024 are presented below: Schedule of Warrants Outstanding and Exercisable Number of Warrants Weighted Average Exercise Price Warrants outstanding at December 31, 2023 260,995 $ 82.55 Issued 530,329 0.90 Expired (43,862 ) 89.60 Warrants outstanding at September 30, 2024 747,462 22.98 Warrants Exercise Price Expiration 10,888 $ 186.00 11/8/2024 153,334 $ 75.00 5/1/2025 52,911 $ 60.00 7/17/2025 70,000 $ 1.88 2/27/2029 55,000 (1) $ 1.25 6/29/2029 405,329 (2) $ 0.69 9/4/2029 1,139,705 (3) $ 0.001 1,887,167 All outstanding warrants are classified as equity on the Company’s Condensed Consolidated Balance Sheets. (1) – Dawson James Placement Agent warrants are not exercisable until December 23, 2024. (2) – Dawson James Placement Agent warrants are not exercisable until March 4, 2025. (3) – Pre-Funded Warrants from September 5, 2024 financing not yet converted as of November 13, 2024.

Stock Compensation Plan (Tables

Stock Compensation Plan (Tables)	9 Months Ended
Stock Compensation Plan (Tables)	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended September 30, 2024 is as follows: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2023 244,733 $ 20.17 8.73 $ 74,559 Granted 799,583 0.48 — $ — Expired (17,146 ) 28.44 — $ — Forfeited (4,667 ) 11.52 — $ — Outstanding at September 30, 2024 1,022,503 $ 4.67 9.06 $ — Exercisable at September 30, 2024 904,853 $ 5.03 8.97 $ — (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2023 and September 30, 2024; respectively.

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($) shares in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Net loss	$ 2,462,870	$ 2,305,090	$ 2,450,833	$ 2,012,885	$ 3,050,586	$ 2,844,837	$ 7,218,795	$ 7,908,308
Operating activities							6,579,029	$ 6,188,335
Accumulated deficit	$ 213,437,047						$ 213,437,047		$ 206,218,254
Aggregate amount of shares							5.6
Gross proceeds from shares sold							$ 7,700,000
Prefunded Warrrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase shares	5						5

Schedule of Prepaid Expense and

Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Prepaid Expense Deposits And Other Current Assets
Prepaid research and development expense, current	$ 386,035
Prepaid insurance	531,701	334,940
Other prepaid expense, current	51,558	47,333
Prepaid research and development expense, long-term	1,090,750	1,090,750
Total prepaid expense, deposits, and other current assets	$ 2,060,044	$ 1,473,023

Schedule of Accounts Payable an

Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts payable trade	$ 1,513,287	$ 1,244,947
Accrued expenses	65,657	222,739
Accrued Vacation	28,170	7,981
Total accounts payable and accrued expenses	$ 1,607,114	$ 1,475,667

Summary of Short-Term Notes Pay

Summary of Short-Term Notes Payable (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Short-term notes payable	$ 519,392	$ 312,703

Summary of Short-Term Notes P_2

Summary of Short-Term Notes Payable (Details) (Parenthetical) - Insurance Premium Financing [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Malpractice Insurance [Line Items]
Debt instrument, face amount	$ 636,972	$ 611,109
Debt instrument, periodic payment	$ 67,277	$ 54,366
Debt instrument, interest rate	9.55%

Shareholders_ Equity (Details N

Shareholders’ Equity (Details Narrative) - USD ($)					3 Months Ended			9 Months Ended
Shareholders’ Equity (Details Narrative) - USD ($)	Sep. 05, 2024	Sep. 04, 2024	Jun. 25, 2024	Mar. 01, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold								5,600,000
Gross proceeds from shares sold								$ 7,700,000
Common stock, par value					$ 0.001			$ 0.001	$ 0.001
Gross proceeds of offering percentage								7%
Common stock, shares issued	8,659,071				9,387,547			9,387,547	3,080,693
Common stock, shares outstanding	8,659,071				9,387,547			9,387,547	3,080,693
Warrants shares outstanding					1,887,167			1,887,167
Proceeds from offering								$ 4,450,000
ONP-002 Product [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from offering								$ 3,790,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued	3,078,378				3,806,854	1,100,000	1,400,000
Warrants to purchase shares of common stock	5,028,206
Pre-Funded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants shares outstanding	5,028,206
Number of shares acquire	5,028,206
Warrants shares exercised	3,888,501
Warrants shares unexercised	1,139,705
Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of warrants exercise price								125%
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Legal fees								$ 125,000
Maximum [Member] \| Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of aggregate number of securities sold								5%
Underwriting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold				1,400,000
Shares sold price per share to public				$ 1.50
Shares sold price per share to underwriter				$ 1.395
Option granted to purchase common shares				210,000
Warrant issuance description				The Company also agreed to issue warrants to the designees of the Representative exercisable one hundred eighty (180) days after February 27, 2024 and expiring on February 27, 2029, to purchase up to 5% of the shares sold through the Underwriting Agreement at an exercise price of $1.875 per share
Warrant exercisable date				Feb. 27, 2024
Warrant maturity date				Feb. 27, 2029
Exercise price per share				$ 1.875
Gross proceeds from shares sold				$ 2,100,000
Placement Agency Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold			1,100,000
Common stock, par value			$ 0.001
Offering price per share			$ 1
Gross proceeds of offering percentage			7%
Gross proceeds of amount before underwriting discounts and commissions and other expenses payable			$ 1,100,000
Placement Agency Agreement [Member] \| Dawson James Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of warrants exercise price			125%
Placement Agency Agreement [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Legal fees			$ 75,000
Placement Agency Agreement [Member] \| Maximum [Member] \| Dawson James Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of aggregate number of securities sold			5%
Second Placement Agency Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold		8,106,584
Common stock, par value		$ 0.001
Offering price per share		0.55
Second Placement Agency Agreement [Member] \| Pre-Funded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price per share		0.001
Offering price per share		$ 0.549

At The Market (Details Narrativ

At The Market (Details Narrative) - USD ($)			9 Months Ended
At The Market (Details Narrative) - USD ($)	Oct. 11, 2024	Aug. 08, 2024	Sep. 30, 2024
Maximum [Member]
Legal fees			$ 125,000
ATM Agreement [Member] \| Subsequent Event [Member]
Commission percentage	3%
Sale of stock, value	$ 10,000,000
Sales Agreement [Member] \| Subsequent Event [Member]
Reimburse fees and disbursements amount	30,000
Sale of stock, value	10,000,000
Sales Agreement [Member] \| Subsequent Event [Member] \| Maximum [Member]
Legal fees	$ 2,500
A T M Issuance Sales Agreement [Member] \| Ascendiant Capital Markets L L C [Member]
Sale of stock, value		$ 10,000,000

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	9 Months Ended
Schedule of Warrants Outstanding and Exercisable (Details)	Sep. 30, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants outstanding, Beginning balance	260,995
Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 82.55
Number of Warrants, Issued	530,329
Weighted Average Exercise Price, Issued \| $ / shares	$ 0.90
Number of Warrants, Expired	(43,862)
Weighted Average Exercise Price, Expired \| $ / shares	$ 89.60
Number of Warrants outstanding, Ending balance	747,462
Weighted Average Exercise Price, Ending balance \| $ / shares	$ 22.98
Warrants Outstanding	1,887,167
Range One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	10,888
Exercise Price \| $ / shares	$ 186
Expiration Date	Nov. 08, 2024
Range Two [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	153,334
Exercise Price \| $ / shares	$ 75
Expiration Date	May 01, 2025
Range Three [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	52,911
Exercise Price \| $ / shares	$ 60
Expiration Date	Jul. 17, 2025
Range Four [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	70,000
Exercise Price \| $ / shares	$ 1.88
Expiration Date	Feb. 27, 2029
Range Five [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	55,000	[1]
Exercise Price \| $ / shares	$ 1.25
Expiration Date	Jun. 29, 2029
Range Six [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	405,329	[2]
Exercise Price \| $ / shares	$ 0.69
Expiration Date	Sep. 04, 2029
Range Seven [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	1,139,705	[3]
Exercise Price \| $ / shares	$ 0.001

[1]– Dawson James Placement Agent warrants are not exercisable until December 23, 2024.[2]– Dawson James Placement Agent warrants are not exercisable until March 4, 2025.[3]– Pre-Funded Warrants from September 5, 2024 financing not yet converted as of November 13, 2024.

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - USD ($)		9 Months Ended	12 Months Ended
Summary of Stock Option Activity (Details) - USD ($)		Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of Shares, Outstanding, Beginning balance		244,733
Weighted Average Exercise Price, Outstanding, Beginning balance		$ 20.17
Weighted Average Remaining Contractual Term (In Years), Outstanding		9 years 21 days	8 years 8 months 23 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	[1]	$ 74,559
Number of Shares, Granted		799,583
Weighted Average Exercise Price, Granted		$ 0.48
Number of Shares, Expired		(17,146)
Weighted Average Exercise Price, Expired		$ 28.44
Number of Shares, Forfeited		(4,667)
Weighted Average Exercise Price, Forfeited		$ 11.52
Number of Shares, Outstanding, Ending balance		1,022,503	244,733
Weighted Average Exercise Price, Outstanding, Ending balance		$ 4.67	$ 20.17
Aggregate Intrinsic Value, Outstanding, Ending balance	[1]		$ 74,559
Number of Shares, Exercisable, Ending balance		904,853
Weighted Average Exercise Price, Exercisable, Ending balance		$ 5.03
Weighted Average Remaining Contractual Term (In Years), Exercisable		8 years 11 months 19 days
Aggregate Intrinsic Value, Exercisable, Ending balance	[1]

[1]The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2023 and September 30, 2024; respectively.

Stock Compensation Plan (Detail

Stock Compensation Plan (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Stock Compensation Plan (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Sep. 29, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized	350,000,000		350,000,000		350,000,000
Number of shares of common stock covered by outstanding option awards	1,022,503		1,022,503		244,733
Stock options compensation cost	$ 330,802	$ 402,805	$ 458,365	$ 546,399
Unrecognized compensation costs related to stock options			$ 195,296
Unrecognized compensation period of recognition			1 year
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period			3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period			10 years
Number of shares of common stock covered by outstanding option awards	1,022,503		1,022,503
Number of shares of common stock available for future awards	3,664		3,664
2021 Equity Incentive Plan [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized	1,166,167		1,166,167
Board of Directors Chairman [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized						1,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 07, 2022	May 31, 2023
Ladenburg [Member]
Loss Contingencies [Line Items]
Invoice amount	$ 2,500,000
Collaborative Research Agreement [Member]
Loss Contingencies [Line Items]
Project cost		$ 1,700,000
Budget project cost percentage		40%